Roivant Sciences Ltd.
ROIVRoivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How ROIV's past catalysts played out
No drugs found in this phase.
treatment of adults with dermatomyositis
1 drug in this indication
dermatomyositis in adults
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
When is Roivant Sciences Ltd.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Roivant Sciences Ltd. (ROIV) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ROIV biotech catalysts?→
Add ROIV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Roivant Sciences Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.